

MAY 2017

FINANCIAL INFORMATION AS OF 31 MARCH 2017 UNLESS OTHERWISE NOTED

# **OVERVIEW**

# NBPE invests in private equity backed companies

### **KEY HIGHLIGHTS**

Listing Date: 2007

Market Capitalisation (5/5/17): £511.3m

Net Asset Value (NAV): \$766.3m

**NAV per Share:** \$15.70 (£12.11)

NAV Total Return – 1 year / 3 year (USD): 16.0% / 34.1%


Share Price Total Return – 1 year / 3 year (GBP): 50.9% / 88.6%

**2017 Avg. Daily Trading Volume**: ~76k shares per day

Current share price (5/5/17): £10.48 (~14% discount)

Dividend Yield (on Share Price): 3.8%

### **INVESTMENT TYPE BY FAIR VALUE**



Note: NBPE data as of 31 March 2017; GBP share price returns converted at daily GBP/USD close FX rates. GBP/USD 5/5/17 rate of \$1.296. Numbers may not sum due to rounding. All performance figures assume re-investment of dividends at NAV or closing share price on the ex-dividend date and reflect cumulative returns over the relevant time periods shown and are not annualised returns; share price return data based on the London Stock Exchange. Average trading volume represents daily average across London Stock Exchange, Euronext Amsterdam and over-the-counter trading platforms.

# **VOTING RIGHTS AND PREMIUM LISTING**

The Company's Class A Shares have been admitted to trading on the premium segment of the London Stock Exchange


# **Recent NBPE Strategic Actions**

- · Class A Shareholders have been granted full voting rights, including for the election of directors
- This has facilitated the transition of the Class A Shares to the Premium Segment of the Main Market of the London Stock Exchange
  - Admitted to trading on 2 May 2017
- The Company's market quote on the London Stock Exchange has been re-denominated into Sterling; no changes to legal form or nature of Class A Shares or the reporting currency
  - NBPE is eligible for inclusion in the FTSE UK Index Series next index review is June 2017
- · Prior to listing, Trudi Clark was appointed as a new director of the Company, replacing Christopher Sherwell

The above actions place NBPE at the forefront of good corporate governance practices and we hope that these changes will open NBPE to a larger buyer universe which may result in increased trading liquidity

# NBPE'S MANAGER: NEUBERGER BERMAN

# Neuberger Berman manages over \$45 billion in Private Equity



### **KEY HIGHLIGHTS**

**Industry Leadership:** 30 years as a private equity investor; committed approximately \$5 billion annually<sup>(2)</sup> to private equity over the past three years

Active Fund Relationships: 400+ with over 270 funds reviewed each year

**Experienced Investors:** Expertise across fund investments, direct investments and income investments

**Deep Team:** Over 115 dedicated private equity investment professionals with extensive networks

**Global Presence:** Investment offices in New York, Dallas, Boston, London, Milan, Hong Kong and Bogota

# LEADING, GLOBAL PRIVATE EQUITY PLATFORM

Note: Represents aggregate committed capital since inception as of January 2017, including commitments in the process of documentation.

- 1. Committed capital from inception through January 2017, including dry powder.
- 2. Average over the past three years (2014 2016).

# NBPE NAV UPDATE

# March 2017 NAV per Share of \$15.70


### **SUMMARY BALANCE SHEET**


(\$ in millions, except per share values)	31 March 2017 (Unaudited)	31 December 2016 (Audited)
Direct Investments		
Income Investments	\$150.8	\$139.0
Equity Investments	447.6	474.9
Total Direct Investments	598.4	613.9
Legacy Fund Investments	144.8	153.4
Total Private Equity Fair Value	743.2	767.3
Private Equity Investment Level	97%	99%
Cash and Cash Equivalents	111.6	93.7
Credit Facility Borrowings	-	-
ZDP Share Liability - 2017	(15.0)	(14.5)
ZDP Share Liability - 2022, including FX Hedge	(66.6)	(62.4)
Net Other Assets (Liabilities), including Minority Interest	(7.0)	(7.5)
Net Asset Value	\$766.3	\$776.6
Net Asset Value per Share	\$15.70	\$15.91
Net Asset Value Plus Dividends Paid During Financial Period	\$15.95	


Note: NBPE data as of 31 March 2017. Numbers may not sum due to rounding.


# NBPE PORTFOLIO DIVERSIFICATION

# Well diversified portfolio weighted to North American investments











Note: as of 31 March 2017. Numbers may not sum due to rounding. Please see endnotes for information on diversification calculations. FOR PROFESSIONAL CLIENT USE ONLY

# **DIVIDENDS AND CAPITAL POSITION**

# Dividends strongly covered by cash distributions and yield from the income portfolio







Note: See endnote #3 for important information related to the dividend. Total yield (inclusive of PIK interest) represents the return (IRR) from this reporting period to the maturity of the investment. As of 31 March 2017.

<sup>1.</sup> Unfunded commitments are adjusted by funds past their investment period and amounts which NBPE has the right to terminate if it so chooses.

<sup>2.</sup> Based on the company's most recent dividend and the London Stock Exchange closing share price of \$13.25 on 31 March 2017 and the 31 March 2017 NAV of \$15.70 per share.

# NBPE DIRECT EQUITY INVESTMENT STRATEGY

Build and maintain a portfolio of direct private equity investments alongside leading private equity firms

- High quality businesses
- Reasonable investment valuations
- · Co-investing alongside Managers in their core areas of expertise
- Bias towards investments with shorter expected time to liquidity

# **INVEST IN NEW DEALS**

# **CO-INVEST "MID-LIFE" INTO EXISTING PRIVATE EQUITY PORTFOLIO COMPANIES**

**PARTIAL REALISATIONS** 

# • Working alongside lead GPs Blue Coat Rac Sabre



# • Provides liquidity to investors Patheon Performance the World Over\* Financial Services Company

# • Provides primary equity to recapitalise balance sheets

# NBPE DIRECT EQUITY PORTFOLIO

# NBPE has a well diversified direct equity portfolio, giving access to growing companies alongside high quality PE sponsors

NBPE DIRECT EQUITY INVESTMENTS
77 direct equity investments with \$447.6 million of fair value
DIVERSIFIED PORTFOLIO
Diversified by industry, geography, company size, vintage year and sponsor
2016 GROWTH <sup>1</sup>
5% LTM Revenue growth / 7% LTM EBITDA growth
VALUATION & LEVERAGE <sup>1</sup>
10.3x EV / EBITDA & 4.7x Net Debt / EBITDA
2017 EXITS <sup>2</sup>
3 Exits generating a 5.0x gross multiple and 44% IRR

TOP TEN INVESTMENTS			
Investment Name	<u>Vintage</u>	<u>Industry</u>	FV (\$m)
Extraction Oil & Gas (NASDAQ: XOG)	2014	Energy	\$30.3
Patheon (NYSE: PTHN)	2014	Healthcare	17.3
The Warranty Group	2014	Fin. Serv.	16.0
ProAmpac	2016	Packaging	16.0
Saguaro	2013	Energy	14.5
Capsugel	2011	Healthcare	13.7
Black Knight Financial Services (NYSE: BKFS)	2013	Financial Services	12.6
Financial Services Company*	2016	Fin. Serv.	12.2
Engineering Ingegneria Informatica	2016	Technology	11.7
Finalsite	2016	Edu. Serv.	11.4
TOP TEN INVESTMENTS			\$155.7

Note: As of 31 March 2017. \*Undisclosed company.

<sup>1.</sup> As of 31 December 2016. Portfolio company operating and valuation metrics are based on the most recently available (unaudited) financial information for each company. Where necessary, estimates were used, which include pro forma adjusted EBITDA and Revenue, annualised quarterly operating metrics and LTM periods as of 31/12/16 and 30/9/16. Data based on 43 traditional buyout companies valued based on EV/EBITDA; excludes companies based on other valuation metrics including book value, revenue multiples, discounted cash flow, latest round of financing and public share price.

<sup>2.</sup> Returns are presented on a "gross" basis (i.e. they do not reflect the management fees, carried interest, transaction costs and other expenses that may be paid by investors, which may be significant and may lower returns)

# NBPE INCOME INVESTMENT STRATEGY

# Since inception, robust deal flow and selectivity have led to strong and stable performance

- Invest in the junior debt of private equity backed businesses
- Use the knowledge and relationships of the NB Private Equity platform for sourcing and due diligence
- Invest on a Primary and Secondary basis

### INVEST IN THE DEBT OF PRIVATE EQUITY BACKED COMPANIES



# **CORPORATE DEBT - SECONDARY**

Mispricings or Dislocations

**Misunderstood Credits** 

- Target smaller, less liquid issuers
- Rigorous fundamental private equity due diligence
- Long-term investment capabilities
- Target equity-like returns in fixed income

# NBPE INCOME PORTFOLIO

# The NBPE income portfolio is well diversified, performing well and has a reasonable average level of total leverage

**TOP TEN INVESTMENTS\*** 

### NBPE INCOME INVESTMENTS

34 income investments with \$150.8 million of fair value

### CASH YIELD & LEVERAGE STATISTICS<sup>1</sup>

- 10.3% cash yield / 10.7% estimated yield to maturity
- 5.6x total leverage / 4.1x senior leverage
- 85% of fair value in floating rate debt
- 57% dividend coverage from portfolio cash yield

### **KEY STATS<sup>2</sup>**

- 80% are in asset light companies
- 87% are in a market leading position<sup>3</sup>
- 56% are in companies with a >40% equity cushion
- 97% are in companies with a >20% equity cushion
- 52% are in companies with a >25% EBITDA margin
- 100% are in performing credits with no covenant issues

Investment Name	Industry	Cash Yield	FV (\$m)
Linxens	Technology	9.5%	10.0
Schumacher Group	Healthcare	9.8%	9.7
Dubois Chemical	Industrials	9.2%	9.0
GCA Services	Bus. Serv.	10.3%	8.9
Funding Circle	Consumer	NA	8.1
Optiv	Technology	8.2%	6.1
ProAmpac	Packaging	9.7%	6.0
Flexera	Technology	8.2%	6.0
Central Security Group	Consumer	10.5%	5.9
Taylor Precision Products	Consumer	13.1%	5.7
TOP TEN INVESTMENTS			\$75.4

Note: As of 31 March 2017. \*Top 10 Investments exclude credit opportunities investments.


<sup>1.</sup> Leverage statistics exclude small business loan programs, credit opportunities and healthcare credit investments. Based on portfolio company data as of 31 December 2016. Small business loan programs are excluded from yield calculations but are at an interest rate at least at the rate stated above.

<sup>2.</sup> Debt key statistics exclude credit opportunities investments, healthcare credit investments and small business loan portfolios.

<sup>3.</sup> Companies have a leading market position in their industry or niche based on NB's due diligence.

# PORTFOLIO INVESTMENT ACTIVITY & LIQUIDITY

# Over \$900 million of distributions since 2014



Note: as of 31 March 2017. Numbers may not sum due to rounding.

# NEW EQUITY & INCOME INVESTMENTS IN 2017 YTD

# \$14.1 million invested in two new equity investments and \$23.5 million invested in four new income investments during 2017 YTD

### **NEW EQUITY INVESTMENTS**

market climate control hicles
maintenance and fleet ices to multiple
d solutions provider
d al government and oftware solutions
d retailer
d emicals for the industry

Note: As of 31 March 2017. New investments exclude investments through the NB Credit Opportunities program.

# **EQUITY REALISATIONS IN 2017**

The below realisations represent \$50 million of total value and a 5.0x multiple of invested capital<sup>1</sup>

INVESTMENT	<u>VINTAGE</u>	DESCRIPTION	OUTCOME
Deltek	2012	<ul> <li>Provider of enterprise software and information solutions for project-focused organisations</li> <li>Has millions of end users with 22,000 organisations in over 80 countries relying on the Deltek platform</li> </ul>	<ul> <li>Sold to Roper Technologies. for \$2.8 billion</li> </ul>
EVANS NETWORK OF COMPANIES	2012	<ul> <li>The Evans Network of Companies is a market-leading provider of intermodal, flatbed, brokerage, dry van and other trucking services</li> <li>Through its agent network, Evans offers services through a fleet of over 3,000 tractors and over 180 terminals throughout the country</li> </ul>	Acquired by Calera Capital
<b>Gabe</b> 's	2012	<ul> <li>Off-price retailer offering well-known brands in apparel and accessories</li> <li>Gabe's operates 106 stores under the Gabe's and Rugged Wearhouse banners across 11 states in the Mid-Atlantic and Southeast</li> </ul>	Sold to Warburg     Pincus

Note: As of 31 March 2017

<sup>1.</sup> Returns are presented on a "gross" basis (i.e. they do not reflect the management fees, carried interest, transaction costs and other expenses that may be paid by investors, which may be significant and may lower returns).

# PERFORMANCE OVERVIEW BY INVESTMENT TYPE

# LTM, three year, and five year investment performance summary

### NBPE PERFORMANCE MEASURED BY GROSS IRR

INVESTMENT TYPE	31 MAR 2017 FAIR VALUE (\$M)	LTM	THREE YEAR	FIVE YEAR
DIRECT EQUITY INVESTMENTS	\$447.6	22.2%	20.2%	19.5%
INCOME INVESTMENTS	\$150.8	16.9%	10.2%	11.9%
FUNDS	\$144.8	5.1%	3.2%	7.4%
TOTAL PORTFOLIO	\$743.2	18.5%	12.7%	13.0%

### **KEY TAKEAWAYS:**


DIRECT EQUITY INVESTMENTS HAVE PERFORMED WELL ACROSS TIME PERIODS

INCOME INVESTMENTS ARE PERFORMING WELL AND HAVE PROVIDED STRONG YIELDS

FUNDS ARE NOW "TAIL-END" AND WINDING DOWN OVER TIME

# **EQUITY EXITS & UPLIFT**

# NBPE has seen strong exits and valuation uplift relative to carrying values



<sup>1.</sup> As of 31 March 2017. Includes full exits only. Excludes partial exits, recapitalisations and IPOs until the stock is fully exited. Year represents the year of final exit. Exit year for public companies determined by the date of the final cash flow. Proceeds include funds that are currently in escrow, but are expected to be received. Returns are presented on a "gross" basis (i.e. they do not reflect the management fees, carried interest, transaction costs and other expenses that may be paid by investors, which may be significant and may lower returns).

NEUBERGER BERMAN

<sup>2.</sup> As of 31 March 2017. Analysis includes eight IPOs, two partial exits, and seventeen full direct equity investment exits since January 2014. For investments which completed an IPO, the value is based on the closing share price on the IPO date; however NBPE remains subject to customary IPO lockup restrictions. Excludes Industry Loss Warranties due to investment duration. Returns are presented on a "gross" basis (i.e. they do not reflect the management fees, carried interest, transaction costs and other expenses that may be paid by investors, which may be significant and may lower returns).

# HISTORIC PERFORMANCE

# Strong NAV and share price performance over the short, medium and long term

### **CUMULATIVE RETURNS OVER TIME**

TOTAL RETURN¹	ONE YEAR	THREE YEAR	FIVE YEAR	SINCE INCEPTION
NET ASSET VALUE USD	16.0%	34.1%	61.0%	83.1%
SHARE PRICE GBP <sup>2</sup>	50.9%	88.6%	190.4%	163.7%

Note: NAV data as of 31 March 2017. Prior to 30 June 2009, NBPE was only listed on the Euronext Amsterdam exchange; the Euronext Amsterdam exchange share price has been substituted for performance calculations prior to this date.


All performance figures assume re-investment of dividends at NAV or closing share price on the ex-divided date and reflect cumulative returns over the relevant time periods shown and are not annualised returns.

GBP share price returns converted at daily GBP/USD close FX rates. See Endnote 5 for USD returns.

# NAV & SHARE PRICE DEVELOPMENT

The move to the premium segment of the LSE and conversion of trading currency to GBP, occurred May 2<sup>nd</sup>, 2017

# NBPE NAV & SHARE PRICE DEVELOPMENT (MAY 2016 - MAY 2017)



<sup>1.</sup> Note: Based on London Stock Exchange price data. As of 5 May 2017. USD share price based on daily close GBP/USD FX rate.

# NBPE - EFFICIENT PRIVATE EQUITY

We believe NBPE offers access to a diverse private equity and income portfolio at a lower cost than many other listed private equity vehicles

# Listed Fund of Funds

- · Charge double layer of fees
  - Often 1.5% 2.0% management fee on committed capital and 20% carry at the underlying fund level in addition to fund of funds fees & carry
- · Hyper-diversified portfolios
- Potential for significant capital structure risk from any over commitment strategy and / or return dilution from cash drag

# Listed Direct Funds

- Single layer of fees, but at a higher level
  - 1.5% management fee on NAV (or NAV + committed capital) and 15 20% carry
- Concentrated lead manager risk and often more concentrated portfolio
- · Multiple "direct" vehicles invest in third party funds and have multiple layers of fees
- Single layer of fees on direct investments

# **NBPE**

- 1.5% on NAV and 7.5% performance fee
- Appropriately diversified with multiple top tier managers
- · Low over commitment risk

# ATTRACTIVE VALUE PROPOSITION

# We believe NBPE offers a compelling investment opportunity

- · Capital appreciation and growth from equity investments
- · Income through an attractive dividend, supported by the cash yield from the income portfolio and investment realisations
- Strong capital structure and commitment coverage
- Private equity exposure with attractive fee structure direct investments in portfolio typically feature lower all-in fees than investing directly into LP funds
- Recent granting of full voting rights to Class A Shareholders and transition to the Premium Segment of the London Stock Exchange
- Eligibility for inclusion in the FTSE UK Index Series may further enhance the Company's trading liquidity




# **APPENDIX**

FOR PROFESSIONAL CLIENT USE ONLY

# FUND INVESTMENT PORTFOLIO LIQUIDITY

NBPE's fund portfolio has continued to produce strong liquidity while becoming an increasingly immaterial component of the overall portfolio



Note: as of 31 December 2016. Numbers may not sum due to rounding.

# **EQUITY INVESTMENTS**

Company Name	Asset Class	Investment Date	Lead Sponsor Fair Value		% of NBPE NAV	
Acteon	Large-cap Buyout	Dec-12	KKR	\$1.4	0.2%	
Alex & Ani	Mid-cap Buyout	May-15	Lion Capital	3.9	0.5%	
American Dental Partners, Inc.	Mid-cap Buyout	Feb-12	JLL Partners	3.8	0.5%	
ARUHI Corporation	Mid-cap Buyout	Oct-14	Carlyle Group	8.9	1.2%	
Aster / DM Healthcare	Mid-cap Buyout	Jun-14	Olympus Capital	6.0	0.8%	
Berlin Packaging	Mid-cap Buyout	Oct-14	Oak Hill Capital Partners	6.7	0.9%	
Black Knight Financial Services	Large-cap Buyout	Dec-13	Thomas H. Lee	12.6	1.6%	
Boa Vista	Mid-cap Buyout	Nov-12	TMG Capital	1.5	0.2%	
Brightview	Large-cap Buyout	Dec-13	KKR	7.2	0.9%	
Capsugel	Large-cap Buyout	Jul-11	KKR	13.7	1.8%	
Centro	Growth / Venture	Jun-15	FTVCapital	3.4	0.4%	
Concord Bio	Growth / Venture	Jun-16	Quadria Capital	3.4	0.4%	
Connector Company*	Growth / Venture	Oct-15	Not Disclosed	4.0	0.5%	
Consilio	Growth / Venture	Jul-15	Shamrock Capital	11.0	1.4%	
Corona Industrials	Mid-cap Buyout	Jun-14	Victoria Capital	2.0	0.3%	
Counsyl	Growth / Venture	Jul-14	Pilot Growth	2.6	0.3%	
CSC Service Works	Mid-cap Buyout	Mar-15	Pamplona Capital	5.8	0.8%	
Digital River (Equity)	Mid-cap Buyout	Feb-15	Siris Capital	9.1	1.2%	
Ellucian	Large-cap Buyout	Sep-15	TPG Capital	7.1	0.9%	
Emerson Network Power	Special Situations	Nov-16	Platinum Equity	8.2	1.1%	
Engineering Ingegneria Informatica	Mid-cap Buyout	May-16	NB Renaissance	11.7	1.5%	
Evans Delivery Company (Equity)	Mid-cap Buyout	Jun-12	AEA Investors	1.3	0.2%	
Evoqua Equity	Mid-cap Buyout	Jan-14	AEA Investors	6.6	0.9%	
Extraction Oil & Gas	Mid-cap Buyout	May-14	Yorktown Partners	30.3	4.0%	
Fairmount Minerals	Mid-cap Buyout	Aug-10	American Securities Partners	1.5	0.2%	
Final Site	Mid-cap Buyout	Nov-16	Bridge Growth Partners	11.4	1.5%	
Financial Services Company*	Large-cap Buyout	Sep-16	Not Disclosed	12.2	1.6%	
First Data	Large-cap Buyout	Sep-07	KKR	3.2	0.4%	
Firth Rixson Equity	Mid-cap Buyout	Dec-07	Oak Hill Capital Partners	0.9	0.1%	
Formation Energy	Mid-cap Buyout	Jul-13	Lindsay Goldberg	1.0	0.1%	
Gabriel Brothers	Special Situations	Mar-12	A&M Capital	0.1	0.0%	
Galco Industrials Equity	Special Situations	May-14	AEA Investors	0.8	0.1%	
Gardner Denver, Inc.	Large-cap Buyout	Jul-13	KKR	7.5	1.0%	
GC Services	Mid-cap Buyout	Jan-16	Owner Resource Group	5.1	0.7%	
Genetic Testing Company - Equity*	Special Situations	Jun-13	Not Disclosed	8.3	1.1%	
Hilsinger	Mid-cap Buyout	May-14	Blue Point Capital	4.9	0.6%	
Incipio	Growth / Venture	Feb-16	Goode Partners	1.6	0.2%	
Inflection Energy	Mid-cap Buyout	Oct-14	Chambers Energy	4.2	0.5%	
Innovation Group	Large-cap Buyout	Dec-15	Carlyle Group	0.6	0.1%	
Into University Partnerships	Mid-cap Buyout	Apr-13	Leeds Equity Partners	1.4	0.2%	

Company Name	Asset Class	Investment Date	Lead Sponsor	Fair Value	% of NBPE NAV
J.Crew Group	Large-cap Buyout	Mar-11	TPG / Leonard Green	0.2	0.0%
Kyobo Life Insurance Co.	Mid-cap Buyout	Dec-07	Corsair Capital Partners	2.2	0.3%
Lasko Products	Special Situations	Nov-16	Comvest Partners	6.5	0.8%
Leaseplan	Mid-cap Buyout	Apr-16	TDR Capital	9.3	1.2%
LGC	Large-cap Buyout	Mar-16	KKR	10.8	1.4%
Lookingglass	Growth / Venture	Feb-15	Alsop Louie	7.1	0.9%
Marquee Brands	Special Situations	Dec-14	Neuberger Berman	10.7	1.4%
MBI Energy	Mid-cap Buyout	Jun-14	Lindsay Goldberg	0.1	0.0%
Medical Diagnostics Company - Equity*	Special Situations	Jan-14	Not Disclosed	0.0	0.0%
MHS	Mid-cap Buyout	Mar-17	Harvest Partners	4.8	0.6%
Mills Fleet Farms	Large-cap Buyout	Feb-16	KKR	4.4	0.6%
Omega Environmental Technologies	Mid-cap Buyout	Feb-17	AEA Investors	9.3	1.2%
Ortholite (Equity)	Mid-cap Buyout	Apr-14	Blue Point Capital	10.6	1.4%
Oticas Carol	Growth / Venture	Apr-13	3i Brazil	3.6	0.5%
Patheon	Mid-cap Buyout	Mar-14	JLL Partners	17.3	2.3%
Petsmart	Large-cap Buyout	Jun-15	BC Partners	10.1	1.3%
ProAmpac	Mid-cap Buyout	Nov-16	Pritzker Group	16.0	2.1%
ProMach	Mid-cap Buyout	Nov-14	AEA Investors	4.6	0.6%
Prosper	Growth / Venture	Apr-15	Multiple Sponsors	2.0	0.3%
RiverBed	Mid-cap Buyout	Feb-15	Thoma Bravo	10.8	1.4%
Sabre Escrow	Large-cap Buyout	Mar-07	NA	0.2	0.0%
Saguaro	Mid-cap Buyout	Jul-13	Pine Brook	14.5	1.9%
Seventh Generation	Growth / Venture	Apr-08	Catamount Ventures	0.2	0.0%
Shelf Drilling	Mid-cap Buyout	Feb-13	Castle Harlan Partners	1.2	0.2%
Snagajob	Growth / Venture	Jun-16	NewSpring Capital	3.5	0.5%
Solace Systems	Growth / Venture	Apr-16	Bridge Growth Partners	8.3	1.1%
SolarWinds	Large-cap Buyout	Feb-16	Thoma Bravo	7.4	1.0%
Specialty Drug Pharma. Company*	Mid-cap Buyout	Oct-15	Not Disclosed	0.8	0.1%
Standard Aero	Mid-cap Buyout	Jun-15	Veritas Capital	6.5	0.8%
Stratus Technologies	Mid-cap Buyout	Apr-14	Siris Capital	2.9	0.4%
Syniverse Technologies	Large-cap Buyout	Feb-11	Carlyle Group	3.0	0.4%
Taylor Precision Products	Mid-cap Buyout	Jul-12	Centre Partners	2.0	0.3%
Technology Company (Encryption App)*	Growth / Venture	Aug-14	Not Disclosed	1.5	0.2%
The Warranty Group	Large-cap Buyout	Jul-14	TPG	16.0	2.1%
Univar	Large-cap Buyout	Nov-10	Clayton, Dublier & Rice	0.8	0.1%
Velocidi	Growth / Venture	Dec-16	Pilot Growth	2.0	0.3%
Vencore	Mid-cap Buyout	Nov-10	Veritas Capital	7.5	1.0%
Net Other Assets / Liabilities				(\$10.8)	n.a.
Total Equity Co-investment Portfolio				\$447.6	59.8%

Note: As of 31 March 2017.

<sup>\*</sup> Due to confidentiality provisions, company name cannot be disclosed.

# **INCOME INVESTMENTS**

NVESTMENT NAME								
Comparted Private Data Newstreamers   Comparted Private Data Newstreamers	INVESTMENT NAME	SECURITY DETAILS			FAIR VALUE <sup>1</sup>			
Second Limit L+7.29%, 1% Fibor, 0.5% OID			DATE	DATE		COUPON	YIELD	YIM
Dept	Corporate Private Debt Investments							
Dubois Chemical   Second Ien. (1-6.07% Coath, 1% L Floor, 1% OD)   Mar-17   Mar-25   3.0   9.2%   9.2%   9.6%   9.6%   Surgard   Second Ien. (1-6.05% Coath, 1% L Floor, 2% OD)   Mar-16   Feb-23   3.8   7.7%   7.9%   8.0%   Surgard   Second Ien. (1-6.05% Coath, 1.0% Coath, 1.0% Coath   Surgard   Second Ien. (1-6.05% Coath, 1.0% L Floor, 2.5% OD)   Mar-16   Mar-24   8.9   10.2%   10.3%   10.7%	2017							
Bub Nile	Optiv	Second Lien (L+7.25%, 1% Floor, 0.5% OID)	Feb-17	Feb-25	6.1	8.3%	8.2%	8.6%
Surgard   Second Lenn (L = 8.59%, 1% Floor; 1.0% OID)	Dubois Chemical	Second lien (L+8.00% Cash, 1% L Floor, 1% OID)	Mar-17	Mar-25	9.0	9.2%	9.2%	9.6%
2016   CAS Enrices	Blue Nile	First Lien (L+6.50% Cash, 1% L Floor, 3% OID)	Mar-17	Feb-23	3.6	7.7%	7.9%	8.0%
CAC Services   Second len (L-9.0% Cash, 1% L Floor, 2.5% OID)   Mar-16   Mar-24   6.0   9.7%   10.2%   10.2%   10.7%	Sungard	Second Lien (L+8.50%, 1% Floor, 1.0% OID)	Feb-17	Jan-25	4.9	9.5%	9.6%	10.0%
ProAmpace   Second Lien (L+8.50%, 1% L Floor)   Nov-16   Oct-24   6.0   9.7%   9.7%   10.1%	2016							
Highbridge Loan Management   Loan portibio   Oct-15   N/A   2.5   N/A   N/A   N/A	GCA Services	Second lien (L+9.0% Cash, 1% L Floor, 2.5% OID)	Mar-16	Mar-24	8.9	10.2%	10.3%	10.7%
Highbridge Loan Management   Loan portfolio   Oct-15   NA   2.5   NA   NA   NA   Lineares   Second lien (1-8.25% Cash, 1.0% L Floor, 1% OID)   Oct-15   Oct-23   10.0   9.4%   9.5%   9.9%   9.9%   Schumacher Group   Second lien (1-8.25% Cash, 1.0% L Floor, 1% OID)   Oct-15   Oct-23   9.7   9.7%   9.8%   10.1%   Purding Circle   Portfolio of small business loans   Jan-15   NA   8.1   NA   NA   NA   NA   NA   NA   NA   N	ProAmpac	Second Lien (L+8.50%, 1% L Floor)	Nov-16	Oct-24	6.0	9.7%	9.7%	10.1%
Linxons   Second len (L+8.25% Cash, 1.0% L Floor, 1% OID)   Oct-15   Oct-23   10.0   9.4%   9.5%   9.9%   Schumacher Group   Second len (L+8.3% Cash, 1.0% L Floor, 1% OID)   Oct-15   Oct-23   9.7   9.7%   9.9%   10.1%	2015							
Schumacher Group   Second lien (L+ 8.5% Cash, 1.0% L Floor, 1% OID)   Oct-15   Oct-23   9,7   9,7%   9,8%   10,1%   Funding Circle	Highbridge Loan Management	Loan portfolio	Oct-15	N/A	2.5	N/A	N/A	N/A
Funding Circle	Linxens	Second lien (L+8.25% Cash, 1.0% L Floor, 1% OID)	Oct-15	Oct-23	10.0	9.4%	9.5%	9.9%
Digital River Debt	Schumacher Group	Second lien (L+8.5% Cash, 1.0% L Floor, 1% OID)	Oct-15	Oct-23	9.7	9.7%	9.8%	10.1%
Digital River Debt   Second lien (L+11.0% Cash, 1.0% L Floor, 1% OID)   Jan-15   Feb-22   1.0   12.2%   11.9%   12.9%	Funding Circle	Portfolio of small business loans	Jan-15	N/A	8.1	N/A	N/A	N/A
2014   Central Security Group   Second lien (L+9.0% Cash, 1, 1/5, Floor, 5% OID)   Nov-14   Cet-21   5.9   10.2%   10.5%   10.7%	Digital River Debt	First lien (L+5.75% Cash, 1.0% L Floor, 1% OID)	Jan-15	Feb-21	1.8	6.9%	7.1%	7.2%
Central Security Group   Second lien (L+9.0% Cash, 1% L Floor, 5% OID)   Nov-14   Oct-21   5.9   10.2%   10.5%   10.7%   Galco Industrial Electronics   Sr. sub notes (10.75% Cash, 1.25% PK, 1.5% OID)   May-14   May-21   5.1   12.0%   10.7%   12.4%   NA   NA   NA   NA   NA   NA   NA   N	Digital River Debt	Second lien (L+11.0% Cash, 1.0% L Floor, 1% OID)	Jan-15	Feb-22	1.0	12.2%	11.9%	12.9%
Galco Industrial Electronics   Sr. sub notes (10.75% Cash, 1.25% PIK, 1.5% OID)   May-14   May-21   5.1   12.0%   10.7%   12.4%   On Deck   Portfolio of small business loans   Apr-14   NIA   0.0   NIA	2014							
On Deck	Central Security Group	Second lien (L+9.0% Cash, 1% L Floor, 5% OID)	Nov-14	Oct-21	5.9	10.2%	10.5%	10.7%
Flexera   Second lien (L+7.0%, 1% L Floor, 0.5% OID)   Apr-14   Apr-21   6.0   8.2%   8.2%   8.5%     2013   Taylor Precision Products   Sr. sub notes (13% Cash, 1.5% OID)   Nov-13   May-19   5.7   13.0%   13.1%   13.8%     P2 Energy Solutions   Second lien (L+8.00% Cash, 1.0% L Floor, 1% OID)   Nov-13   May-21   4.1   9.2%   11.3%   9.9%     Total Corporate Private Debt Investments Fair Value   \$98.3   7.3%   9.9%   10.3%     Total Credit Opportunities Investments   \$98.3   7.3%   9.9%   13.9%     Healthcare Credit Investments	Galco Industrial Electronics	Sr. sub notes (10.75% Cash, 1.25% PIK, 1.5% OID)	May-14	May-21	5.1	12.0%	10.7%	12.4%
Taylor Precision Products   Sr. sub notes (13% Cash, 1.5% OID)   Nov-13   May-19   5.7   13.0%   13.1%   13.8%   13.8%   P2 Energy Solutions   Second lien (L+8.00% Cash, 1.0% L Floor, 1% OID)   Nov-13   May-21   4.1   9.2%   11.3%   9.9%   10.3%   Nov-13   Nov-1	On Deck	Portfolio of small business loans	Apr-14	N/A	0.0	N/A	N/A	N/A
Taylor Precision Products   Sr. sub notes (13% Cash, 1.5% OID)   Nov-13   May-19   5.7   13.0%   13.1%   13.8%   P2 Energy Solutions   Second lien (L+8.00% Cash, 1.0% L Floor, 1% OID)   Nov-13   May-21   4.1   9.2%   11.3%   9.9%   Total Corporate Private Debt Investments Fair Value   \$98.3   7.3%   9.9%   10.3%	Flexera	Second lien (L+7.0%, 1% L Floor, 0.5% OID)	Apr-14	Apr-21	6.0	8.2%	8.2%	8.5%
P2 Energy Solutions   Second lien (L+8.00% Cash, 1.0% L Floor, 1% OID)   Nov-13   May-21   4.1   9.2%   11.3%   9.9%     Total Corporate Private Debt Investments Fair Value   \$98.3   7.3%   9.9%   10.3%     Total Credit Opportunities Investments   \$98.3   7.3%   9.9%   10.3%     Total Credit Investments   \$98.3   7.3%   9.9%   13.9%     Healthcare Credit Investments	2013							
Total Corporate Private Debt Investments Fair Value   \$98.3   7.3%   9.9%   10.3%	Taylor Precision Products	Sr. sub notes (13% Cash, 1.5% OID)	Nov-13	May-19	5.7	13.0%	13.1%	13.8%
Food   Credit Opportunities   Investments   S38.5   9.3%   9.9%   13	P2 Energy Solutions	Second lien (L+8.00% Cash, 1.0% L Floor, 1% OID)	Nov-13	May-21	4.1	9.2%	11.3%	9.9%
Healthcare Credit Investments	Total Corporate Private Debt Investments Fair Value				\$98.3	7.3%	9.9%	10.3%
Serior Secured term loan (L + 5.375%, 1% Floor)   Jan-16   Jan-23   - 6.4%   6.9%   6.6%	Total Credit Opportunities Investments				\$38.5	9.3%	9.9%	13.9%
Converted Pharmaceutical Company   Senior secured term loan (L + 5.375%, 1% Floor)   Jan-16   Jan-23   - 6.4%   6.9%   6.6%	Healthcare Credit Investments							
Second lien (L+8.50%, 1% L Floor, 6% OID)   Mar-15   Dec-22   - 9.5%   10.1%   10.0%	2016							
Term Loan (Medical Implants)	Generic Pharmaceutical Company	Senior secured term loan (L + 5.375%, 1% Floor)	Jan-16	Jan-23	-	6.4%	6.9%	6.6%
Royally Notes (Biotechnology)   Royally backed note (9.375% Cash)   Mar-15   Mar-26   - 9.4%   9.1%   9.8%	2015	· · · · · · · · · · · · · · · · · · ·						
2014   Convertible Notes (Specialty Pharmaceuticals)   Convertible notes (4.5% Cash)   Apr-14   May-20   - 4.5%   6.5%   4.6%	Term Loan (Medical Implants)	Second lien (L+8.50%, 1% L Floor, 6% OID)	Mar-15	Dec-22	-	9.5%	10.1%	10.0%
Convertible Notes (Specialty Pharmaceuticals)   Convertible notes (4.5% Cash)   Apr-14   May-20   - 4.5%   6.5%   4.6%	Royalty Notes (Biotechnology)	Royalty backed note (9.375% Cash)	Mar-15	Mar-26	-	9.4%	9.1%	9.8%
Term Loan (Specially PCP and Pediatric Pharmaceuticals)   Senior secured loan (first lien, 12% cash, 0.75% fee)   Feb-14   Feb-19   - 12.0%   13.7%   12.7%	2014							
Term Loan (Medical Diagnostics)   Senior secured loan (10.5% Cash)   Jan-14   Dec-18   - 10.5%   10.9%   11.0%	Convertible Notes (Specialty Pharmaceuticals)	Convertible notes (4.5% Cash)	Apr-14	May-20	-	4.5%	6.5%	4.6%
2013         Jul-13         Jul-13         Jul-18         -         10.5%         N/M         N/M           Term Loan (Skin Products Company)         Senior secured loan (First Lien, 10.5% Cash, 1.5% Fee)         Jul-13         Jul-18         -         10.5%         10.5%         10.5%           Royally Notes (Hormone Therapy)         Royally backed note         Apr-11         N/A         -         N/A         N/M         N/M           Total Healthcare Credit Investments Fair Value         \$14.0         8.9%         10.2%         8.6%	Term Loan (Specialty PCP and Pediatric Pharmaceuticals)	Senior secured loan (first lien, 12% cash, 0.75% fee)	Feb-14	Feb-19	-	12.0%	13.7%	12.7%
Term Loan (Skin Products Company)         Senior secured loan (First Lien, 10.5% Cash, 1.5% Fee)         Jul-13         Jul-18         -         10.5%         N/M         N/M           Term Loan (Genetic Testing)         Senior secured loan (First Lien, 10% Cash, 1% Fee)         Jun-13         Jun-18         -         10.0%         10.2%         10.5%           Royalty Notes (Hormone Therapy)         Royalty backed note         Apr-11         N/A         -         N/A         N/M         N/M           Total Healthcare Credit Investments Fair Value         \$14.0         8.9%         10.2%         8.6%	Term Loan (Medical Diagnostics)	Senior secured Ioan (10.5% Cash)	Jan-14	Dec-18	-	10.5%	10.9%	11.0%
Term Loan (Genetic Testing)         Senior secured loan (First Lien, 10% Cash, 1% Fee)         Jun-13         Jun-18         -         10.0%         10.2%         10.5%           Royalty Notes (Hormone Therapy)         Royalty backed note         Apr-11         N/A         -         N/A         N/M         N/M           Total Healthcare Credit Investments Fair Value         \$14.0         8.9%         10.2%         8.6%	2013							
Royally Notes (Hormone Therapy)         Royally backed note         Apr-11         N/A         -         N/A         N/M         N/M           Total Healthcare Credit Investments Fair Value         \$14.0         8.9%         10.2%         8.6%	Term Loan (Skin Products Company)	Senior secured loan (First Lien, 10.5% Cash, 1.5% Fee)	Jul-13	Jul-18	-	10.5%	N/M	N/M
Total Healthcare Credit Investments Fair Value \$14.0 8.9% 10.2% 8.6%	Term Loan (Genetic Testing)	Senior secured loan (First Lien, 10% Cash, 1% Fee)	Jun-13	Jun-18	-	10.0%	10.2%	10.5%
The state of the s	Royalty Notes (Hormone Therapy)	Royalty backed note	Apr-11	N/A	-	N/A	N/M	N/M
Total Income Portfolio Fair Value \$150.8 8.7% 10.3% 10.7%	Total Healthcare Credit Investments Fair Value				\$14.0	8.9%	10.2%	8.6%
	Total Income Portfolio Fair Value				\$150.8	8.7%	10.3%	10.7%

Note: As of 31 March 2017.

See endnote #3 for important information on the income investment portfolio.
 Due to confidentiality provisions, company name cannot be disclosed.

# **FUND INVESTMENTS**

Investment Name	Asset Class	Vintage Year	Unfunded Commitment	Fair Value	% of NBPE NAV
Catalyst Fund III	Special Situations Funds	2011	\$0.7	\$15.2	2.0%
NB Crossroads Fund XVIII - Mid-cap Buyout	Mid-cap Buyout Funds	Fund XVIII	7.1	12.8	1.7%
NB Crossroads Fund XVII	Fund XVII (Diversified)	Fund XVII	1.7	9.7	1.3%
Bertram Growth Capital II	Growth / Venture Funds	2010	1.8	9.0	1.2%
Platinum Equity Capital Partners II	Special Situations Funds	2007	3.3	7.9	1.0%
OCM Principal Opportunities Fund IV	Mid-cap Buyout Funds	2007	2.0	7.6	1.0%
Sun Capital Partners V	Special Situations Funds	2007	1.1	6.7	0.9%
NB Crossroads Fund XVIII - Venture Capital	Growth / Venture Funds	Fund XVIII	1.7	6.6	0.9%
Avista Capital Partners	Mid-cap Buyout Funds	2006	0.2	6.5	0.8%
Bertram Growth Capital I	Growth / Venture Funds	2007	1.1	6.3	0.8%
NG Capital Partners I , L.P.	Growth / Venture Funds	2010	0.5	6.6	0.9%
NB Crossroads Fund XVIII - Large-cap Buyout	Large-cap Buyout Funds	Fund XVIII	2.2	4.1	0.5%
Corsair III Financial Services Capital Partners	Mid-cap Buyout Funds	2007	0.9	5.6	0.7%
Sankaty Credit Opportunities III	Special Situations Funds	2007	0.0	3.6	0.5%
ArcLight Energy Partners Fund IV	Mid-cap Buyout Funds	2007	4.6	2.5	0.3%
NB Crossroads Fund XVIII - Special Situations	Special Situations Funds	Fund XVIII	0.9	3.6	0.5%
Oaktree Opportunities Fund VIII	Special Situations Funds	2009	0.0	2.8	0.4%
NB Fund of Funds Secondary 2009	Mid-cap Buyout Funds	2009	0.7	3.0	0.4%
Highstar Capital Fund II	Mid-cap Buyout Funds	2004	0.1	2.9	0.4%
OCM Opportunities Fund VIIb	Special Situations Funds	2008	3.0	2.2	0.3%
CVI Global Value Fund	Special Situations Funds	2006	0.8	2.2	0.3%
First Reserve Fund XI	Large-cap Buyout Funds	2006	0.0	2.6	0.3%
DBAG Expansion Capital Fund	Growth / Venture Funds	2012	1.2	3.0	0.4%
Aquiline Financial Services Fund L.P.	Mid-cap Buyout Funds	2005	0.0	2.5	0.3%
Trident IV	Mid-cap Buyout Funds	2007	0.5	1.9	0.2%
J.C. Flowers II	Large-cap Buyout Funds	2006	0.3	2.2	0.3%
Lightyear Capital Fund II	Mid-cap Buyout Funds	2006	1.4	1.7	0.2%
Centerbridge Credit Partners	Special Situations Funds	2008	0.0	1.0	0.1%
American Capital Equity II	Mid-cap Buyout Funds	2005	1.2	0.7	0.1%
Carlyle Europe Partners II	Large-cap Buyout Funds	2003	0.6	0.8	0.1%
Strategic Value Global Opportunities Fund I-A	Special Situations Funds	2010	0.1	0.4	0.1%
Strategic Value Special Situations Fund	Special Situations Funds	2010	0.0	0.2	0.0%
Clessidra Capital Partners	Mid-cap Buyout Funds	2004	0.1	0.0	0.0%
Prospect Harbor Credit Partners	Special Situations Funds	2007	0.0	0.1	0.0%
Total Fund Portfolio			\$39.6	\$144.8	18.9%

Note: As of 31 March, 2017.

# TRADING INFORMATION

Trading Symbol:	Class A Ordinary Shares: NBPE
Exchanges:	Euronext Amsterdam & London Stock Exchange
Base Currency:	USD
Bloomberg:	NBPE NA, NBPE LN
Reuters:	NBPE.AS, NBPE.L
ISIN:	GG00B1ZBD492
COMMON:	030991001

Trading Symbol:	2017 ZDPs / 2022 ZDPs: NBPZ / NBPP
Exchanges:	London Stock Exchange & The International Stock Exchange
Base Currency:	GBP
Bloomberg:	NBPEGBP LN / NBPP:LN
Reuters:	NBPEO.L
ISIN:	GG00B4ZXGJ22 / GG00BD0FRW63
SEDOL:	B4ZXGJ2 / BD0FRW6
Gross Redemption Yield at Issuance:	7.30% / 4.0%
Share Life:	31 May 2017 / 30 September 2022
Final Capital Entitlement:	169.73p / 126.74p

# **CONTACT INFORMATION**

Registered Office:	NB Private Equity Partners Limited P.O. Box 225 Heritage Hall, Le Marchant Street St. Peter Port, Guernsey GY1 4HY Channel Islands Tel: +44.(0).1481.716.000
Investment Manager:	NB Alternatives Advisers LLC 325 N. Saint Paul Street Suite 4900 Dallas, TX 75201 United States of America
Investor Relations:	Web: www.nbprivateequitypartners.com Email: IR_NBPE@nb.com Tel: +1.214.647.9593
Media Relations:	Neustria Partners Nick Henderson Tel: +44.20.3021.2583

Corporate Brokers:	Stifel Nicolaus Neil Winward Tel: +44.20.7710.7600
	Jefferies International Limited Gary Gould/Stuart Klein Tel: +44.20.7029.8766
Research Analysts:	Stifel Nicolaus- Iain Scouller Email: iain.scouller@stifel.com
	Jefferies – Mark Ambrose, CFA Email: mambrose@jefferies.com
	J.P. Morgan Cazenove – Christopher Brown Email: christopher.brown@jpmorgan.com
	Canaccord Genuity – Alan Brierley Email: abrierley@canaccordgenuity.com
	Fidante – Tom Skinner Email: tskinner@fidante.com
	Liberum Capital – Coner Finn Email: coner.finn@liberumcapital.com
	Numis – Charles Cade & Sarah Lewandowski Email: c.cade@numis.com
	Winterflood – Simon Elliott Email: simon.elliott@wins.co.uk

# **ENDNOTES**

- 1. The diversification analysis by geography, industry and vintage is based on the fair value of underlying fund investments and direct/co-investments; the diversification analysis for company size is based on the fair value of the underlying direct/co-investments and the fair value of funds with a focus on the company size described. Determinations regarding geography, industry, vintage and company size represent the Investment Manager's estimates. Accordingly, the actual diversification of our investment portfolio and the diversification of our investment portfolio on an ongoing basis may vary from the foregoing information. For the NB Alternatives Direct Co-investment Program and the NB Healthcare Credit Investment Program commitments, total exposure only reflects the funded investments to date. Unfunded amounts and unfunded percentages within each of these programs are excluded from the analysis, as capital deployment is opportunistic and cannot be accurately forecast at this time.
- 2. Guidance regarding NBPE's future portfolio and performance is a target only and not a profit forecast. There can be no assurance that this target will be met or that the Company will make any future distributions whatsoever. Any such changes will be notified to shareholders through a regulatory information service. NBPE's Board of Directors will continue to evaluate the Company's financial position, annual dividend target and the timing of future dividends. Future dividend payments will be announced by NBPE after the Board of Directors have completed such evaluation.
- 3. Yield to maturities represent the return (IRR) from this reporting period to maturity of the investment. Includes a portfolio of small business loans at an interest rate at least at the rate stated above but not included in the yield calculations. The Taylor Precision Products debt notes currently pay 13% cash, but issuer has the option to pay 11% and 2% PIK.
- 4. Actual unfunded commitments are \$261.7 million at 31 March 2017, corresponding to actual under commitment of \$0.1 million and an actual commitment coverage ratio of 100.0%. Unfunded adjustments include removing unfunded commitments to funds past their investment period (although some amount may be called for future follow-ons or expenses), and amounts which can be terminated by NBPE if it so chooses.
- 5. USD share price returns are: 31.2% (one year), 41.7% (three year), 127.4% (five year) and 61.5% (since inception)

NEUBERGER BERMAN 28

# LEGAL DISCLAIMER

THE CONTENTS OF THIS DOCUMENT AND THE PRESENTATION ARE STRICTLY CONFIDENTIAL AND MAY NOT BE COPIED, DISTRIBUTED, PUBLISHED OR REPRODUCED IN WHOLE OR IN PART, OR DISCLOSED OR DISTRIBUTED BY RECIPIENTS TO ANY OTHER PERSON. ANY RECIPIENT OF THIS DOCUMENT AGREES TO KEEP PERMANENTLY CONFIDENTIAL ALL INFORMATION HEREIN NOT ALREADY IN THE PUBLIC DOMAIN.

This document and the presentation are not for release, publication or distribution (directly or indirectly) in or into the United States, Canada, Australia or Japan or to any "US person" as defined in Regulation S under the United States Securities Act of 1933, as amended (the "Securities Act") or into any other jurisdiction where applicable laws prohibit its release, distribution or publication. It does not constitute an offer of securities for sale anywhere in the world, including in or into the United States, Canada, Australia or Japan. No recipient may distribute, or make available, this document or the presentation (directly or indirectly) to any other person. Recipients of this document and the presentation should inform themselves about and observe any applicable legal requirements in their jurisdictions. In particular, the distribution of this document and the presentation may in certain jurisdictions be restricted by law. Accordingly, recipients represent that they are able to receive this document and relating presentation without contravention of any applicable legal or regulatory restrictions in the jurisdiction in which they reside or conduct business.

This document and the presentation have been prepared by NB Private Equity Partners Limited ("NBPE") and NB Alternatives Advisers LLC (the "Investment Manager"). No member of the Neuberger Berman Group nor any of their respective directors, officers, employees, advisors, representatives, or other agents makes or has been authorised to make any representation or warranties (express or implied) in relation to NBPE or as to the truth, accuracy or completeness of this document or the presentation, or any other written or oral statement provided. In particular, no representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on any projections, targets, estimates or forecasts contained in this document or the presentation and nothing in this document or the presentation is or should be relied on as a promise or representation as to the future. The name "Neuberger Berman" is used interchangeably throughout these materials for a number of entities that are part of, or are associated with, the Neuberger Berman Group and when used in this notice includes all such entities.

This document does not constitute a prospectus or offering memorandum or an offer in respect of any securities and is not intended to provide the basis for any decision in respect of NBPE or other evaluation of any securities of NBPE or any other entity and should not be considered as a recommendation that any investor should subscribe for or purchase any such securities. Neither the issue of this document nor the presentation nor any part of their contents constitutes an offer to sell or invitation to purchase any securities of NBPE or any other entity or any persons holding securities of NBPE and no information set out in this document or the presentation or referred to in other written or oral information is intended to form the basis of any contract of sale, investment decision or any decision to purchase any securities referred to in it.

The information contained in this document is given at the date of its publication (unless otherwise marked) and is subject to updating, revision and amendment. No reliance may be placed for any purpose whatsoever on the information of opinions contained in this document or on its completeness, accuracy or fairness. The contents of this document have not been approved by any competent regulatory or supervisory authority.

This document, any presentation made in conjunction with this document and any accompanying materials (the "Information Materials") are made available for information purposes only. The Information Materials, which are not a prospectus or listing particulars or an admission document, do not contain any representations, do not constitute or form part of any offer or invitation to sell or transfer, or to underwrite, subscribe for or acquire, any shares or other securities, and do not constitute or form any part of any solicitation of any such offer or invitation, nor shall they are or any part of them or the fact of their distribution form the basis of or be relied upon in connection with any contract therefore, and do not constitute a recommendation regarding the securities of NBPE.

Neither NBPE nor Neuberger Berman gives any undertaking to provide the recipient with access to any additional information, or to update this document, the presentation or any additional information, or to correct any inaccuracies in it which may become apparent and the distribution of this document and the presentation shall not be deemed to be any form of commitment on the part of NBPE, the Investment Manager or Neuberger Berman to proceed with any transaction.

FOR PROFESSIONAL CLIENT USE ONLY 29

# LEGAL DISCLAIMER

THE PROMOTION OF NBPE AND THE DISTRIBUTION OF THIS DOCUMENT AND THE PRESENTATION IN THE UNITED KINGDOM IS RESTRICTED BY LAW. ACCORDINGLY, THIS COMMUNICATION IS DIRECTED ONLY AT (I) PERSONS OUTSIDE THE UNITED KINGDOM TO WHOM IT IS LAWFUL TO COMMUNICATE TO, OR (II) PERSONS HAVING PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS WHO FALL WITHIN THE DEFINITION OF "INVESTMENT PROFESSIONALS" IN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (AS AMENDED), OR (III) HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS AND PARTNERSHIPS AND TRUSTESS OF HIGH VALUE TRUSTS AS DESCRIBED IN ARTICLE 49(2) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (AS AMENDED); PROVIDED THAT IN THE CASE OF PERSONS FALLING INTO CATEGORIES (II) OR (III), THE COMMUNICATION IS ONLY DIRECTED AT PERSONS WHO ARE ALSO "QUALIFIED INVESTORS" AS DEFINED IN SECTION 86 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (EACH A "RELEVANT PERSON"). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS COMMUNICATION RELATES IS AVAILABLE ONLY TO AND WILL BE ENGAGED IN ONLY WITH SUCH RELEVANT PERSONS. PERSONS WITHIN THE UNITED KINGDOM WHO RECEIVE THIS COMMUNICATION (OTHER THAN PERSONS FALLING WITHIN (II) AND (III) ABOVE) SHOULD NOT RELY ON OR ACT UPON THIS COMMUNICATION. YOU REPRESENT AND AGREE THAT YOU ARE A RELEVANT PERSON.

NBPE HAS NOT BEEN, AND HAS NO INTENTION TO BE, REGISTERED UNDER THE U.S. INVESTMENT COMPANY ACT OF 1940, AS AMENDED (THE "INVESTMENT COMPANY ACT") AND INVESTORS WILL NOT BE ENTITLED TO THE BENEFITS OF THAT ACT. THE SECURITIES DESCRIBED IN THIS DOCUMENT HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT. CONSEQUENTLY, SUCH SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS (AS SUCH TERM IS DEFINED IN REGULATION S UNDER THE SECURITIES ACT) UNLESS SUCH SECURITIES ARE REGISTERED UNDER THE SECURITIES ACT OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENT OF THE SECURITIES ACT IS AVAILABLE. NO PUBLIC OFFERING OF THE SECURITIES IS BEING MADE IN THE UNITED STATES.

PROSPECTIVE INVESTORS SHOULD TAKE NOTE THAT ANY SECURITIES MAY NOT BE ACQUIRED BY INVESTORS USING ASSETS OF ANY RETIREMENT PLAN OR PENSION PLAN THAT IS SUBJECT TO PART 4 OF SUBTITLE B OF TITLE I OF THE UNITED STATES EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974, AS AMENDED ("ERISA") OR SECTION 4975 OF THE UNITED STATES INTERNAL REVENUE CODE OF 1986, AS AMENDED (THE "CODE"), ENTITIES WHOSE UNDERLYING ASSETS ARE CONSIDERED TO INCLUDE "PLAN ASSETS" OF ANY SUCH RETIREMENT PLAN OR PENSION PLAN, OR ANY GOVERNMENTAL PLAN, CHURCH PLAN, NON-U.S. PLAN OR OTHER INVESTOR SUBJECT TO ANY STATE, LOCAL, NON-U.S. OR OTHER LAWS OR REGULATIONS SIMILAR TO TITLE I OR ERISA OR SECTION 4975 OF THE CODE OR THAT WOULD HAVE THE EFFECT OF THE REGULATIONS ISSUED BY THE UNITED STATES DEPARTMENT OF LABOR SET FORTH AT 29 CFR SECTION 2510.3-101. AS MODIFIED BY SECTION 3(42) OF ERISA.

THE MERITS OR SUITABILITY OF ANY SECURITIES MUST BE INDEPENDENTLY DETERMINED BY THE RECIPIENT ON THE BASIS OF ITS OWN INVESTIGATION AND EVALUATION OF NBPE, THE INVESTMENT MANAGER, AND NEUBERGER BERMAN. ANY SUCH DETERMINATION SHOULD INVOLVE, AMONG OTHER THINGS, AN ASSESSMENT OF THE LEGAL, TAX, ACCOUNTING, REGULATORY, FINANCIAL, CREDIT AND OTHER RELATED ASPECTS OF THE SECURITIES. RECIPIENTS OF THIS DOCUMENT AND THE PRESENTATION ARE RECOMMENDED TO SEEK THEIR OWN INDEPENDENT LEGAL, TAX, FINANCIAL AND OTHER ADVICE AND SHOULD RELY SOLELY ON THEIR OWN JUDGMENT, REVIEW AND ANALYSIS IN EVALUATING NBPE, THE INVESTMENT MANAGER, AND NEUBERGER BERMAN, AND THEIR BUSINESS AND AFFAIRS.

THIS DOCUMENT AND THE PRESENTATION MAY CONTAIN CERTAIN FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS RELATE TO EXPECTATIONS, BELIEFS, PROJECTIONS, FUTURE PLANS AND STRATEGIES, ANTICIPATED EVENTS OR TRENDS AND SIMILAR EXPRESSIONS CONCERNING MATTERS THAT ARE NOT HISTORICAL FACTS. IN SOME CASES, FORWARD-LOOKING STATEMENTS CAN BE INDENTIFIED BY TERMS SUCH AS "ANTICIPATE", BELIEVE", "COULD", "ESTIMATE", "EXPECT", "INTEND", "MAY", "PLAN", "POTENTIAL", "SHOULD", "WILL", AND "WOULD", OR THE NEGATIVE OF THOSE TERMS OR OTHER COMPARABLE TERMINOLOGY. THE FORWARD-LOOKING STATEMENTS ARE BASED ON NBPE'S AND/OR NEUBERGER BERMAN'S BELIEFS, ASSUMPTIONS, AND EXPECTATIONS OF FUTURE PERFORMANCE AND MARKET DEVELOPMENTS, TAKING INTO ACCOUNT ALL IN FORWARD-LOOKING STATEMENTS OF FUTURE PERFORMANCE AND MARKET DEVELOPMENTS, TAKING INTO ACCOUNT ALL IN FORWARD-LOOKING STATEMENTS. OR FUTURE PERFORMANCE AND MARKET DEVELOPMENTS, TAKING INTO ACCOUNT ALL IN FORWARD-LOOKING STATEMENTS. OR FUTURE PERFORMANCE AND MARKET DEVELOPMENTS, TAKING INTO ACCOUNT ALL IN FORWARD-LOOKING STATEMENTS. OR FUTURE PERFORMANCE AND MARKET DEVELOPMENTS, TAKING INTO ACCOUNT ALL IN FORWARD-LOOKING STATEMENTS. OR FUTURE PERFORMANCE AND MARKET DEVELOPMENTS, TAKING INTO ACCOUNT ALL INFORMANCE AND MARKET DEVELOPMENTS, TAKING INTO ACCOUNT ALL INFORMANCE AND MARKET DEVELOPMENTS, THE FORMANCE AND ACCOUNT AND

BY THEIR NATURE, FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES BECAUSE THEY RELATE TO EVENTS, AND DEPEND ON CIRCUMSTANCES THAT MAY OR MAY NOT OCCUR IN THE FUTURE. FORWARD-LOOKING STATEMENTS ARE ONLY MADE AS AT THE DATE OF THIS DOCUMENT AND THE PRESENTATION, AND NEITHER NBPE NOR THE INVESTMENT MANAGER ASSUMES ANY OBLIGATION TO UPDATE FORWARD-LOOKING STATEMENTS SET FORTH IN THIS DOCUMENT WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS, OR OTHERWISE, EXCEPT AS REQUIRED BY LAW OR OTHER APPLICABLE REGULATION. IN LIGHT OF THESE RISKS, UNCERTAINTIES, AND ASSUMPTIONS, THE EVENTS DESCRIBED BY ANY SUCH FORWARD-LOOKING STATEMENTS BY THESE CAUTIONARY FACTORS. PLEASE KEEP THIS CAUTIONARY NOTE IN MIND WHILE READING THIS DOCUMENT.

# LEGAL DISCLAIMER

BY ACCEPTING AND READING THIS DOCUMENT AND/OR ATTENDING THE PRESENTATION TO WHICH THIS DOCUMENT RELATES YOU WILL BE DEEMED TO HAVE REPRESENTED, WARRANTED AND UNDERTAKEN FOR THE BENEFIT OF NBPE, THE INVESTMENT MANAGER, NEUBERGER BERMAN AND OTHERS THAT (A) YOU ARE OUTSIDE OF THE UNITED STATES AND ARE AN "INVESTMENT PROFESSIONAL" (AS DEFINED ABOVE), (B) YOU HAVE READ AND AGREE TO COMPLY WITH THE CONTENTS OF THIS NOTICE, YOU WILL KEEP THE INFORMATION IN THIS DOCUMENT AND DELIVERED DURING ANY PRESENTATION OR CONTAINTED IN ANY ACCOMPANYING DOCUMENT AND ALL INFORMATION ABOUT NEUBERGER BERMAN CONFIDENTIAL, AND WILL NOT REPRODUCE OR DISTRIBUTE, IN WHOLE OR IN PART, (DIRECTLY) OR INDIRECTLY) ANY SUCH INFORMATION, UNTIL SUCH INFORMATION HAS BEEN MADE PUBLICLY AVAILABLE AND TAKE ALL REASONABLE STEPS TO PRESERVE SUCH CONFIDENTIALITY, AND (C) YOU ARE PERMITTED, IN ACCORDANCE WITH APPLICABLE LAWS, TO RECEIVE SUCH INFORMATION.

NBPE IS ESTABLISHED AS A CLOSED-END INVESTMENT COMPANY IN GUERNSEY AND THE COMPANY IS SUBJECT TO THE NETHERLANDS FINANCIAL SUPERVISION ACT (WET OP HET FINANCIEL TOEZICHT, "WFT"), AS A LISTED ENTITY (UITGEVENDE INSTELLING) AS DEFINED IN SECTION 1:1 OF THE WFT. ALL INVESTMENTS ARE SUBJECT TO RISK. PAST PERFORMANCE IS NO GUARANTEE OF FUTURE RETURNS. PROSPECTIVE INVESTORS ARE ADVISED TO SEEK EXPERT LEGAL, FINANCIAL, TAX AND OTHER PROFESSIONAL ADVICE BEFORE MAKING ANY INVESTMENT DECISION. THE VALUE OF INVESTMENTS MAY FLUCTUATE. RESULTS ACHIEVED IN THE PAST ARE NO GUARANTEE OF FUTURE RESULTS.

THIS DOCUMENT IS ISSUED BY NBPE WHOSE REGISTERED ADDRESS IS AT HERITAGE HALL, PO BOX 225, LE MARCHANT STREET, ST. PETER PORT, GUERNSEY GY1 4HY. NB ALTERNATIVES ADVISERS LLC IS A REGISTERED INVESTMENT ADVISER IN THE UNITED STATES. NEUBERGER BERMAN IS A REGISTERED TRADEMARK. ALL RIGHTS RESERVED. ©2017 NB ALTERNATIVES ADVISERS LLC.